Navigation Links
Pharmasset Receives Notice of Allowance
Date:6/26/2008

ected.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Kurt Leutzinger

Chief Financial Officer

kurt.leutzinger@pharmasset.com

Office: +1 (609) 613-4110

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that the USPTO will withdraw the Notice of Allowance, adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that we cannot enroll enough patients for the Phase 3 registration clinical trial for clevudine, the risk that our collaboration with
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014  Chuma Holdings, Inc. (OTCBB:CHUM) ... and turnkey support services for the lawfully organized ... processed and approved the Company,s name and symbol ... Corporation will be known as Chuma Holdings, Inc. ... through a merger with the Company,s wholly-owned subsidiary, ...
(Date:8/29/2014)... , Aug. 29, 2014 The Competitive Intelligence ... and marketplace changes. CI leaders who adjust will succeed, ... In a new Best Practices, LLC study CI leaders ... insights, including: - Use secondary research whenever ... research - Internal staff who are creative ...
(Date:8/29/2014)... Pomerantz LLP has filed a class action ... EDAP ) and certain of its officers.  ... Southern District of New York , ... class consisting of all persons or entities who purchased ... 2014, inclusive (the "Class Period"). This class action seeks to ...
Breaking Medicine Technology:CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3
... N.C. , Feb. 4 Gorbec Pharmaceutical ... prescription pharmaceutical products, is opening a GMP-compliant analytical laboratory ... expand Gorbec,s current services for analytical method development and ... its U.S. customer base as well as develop a ...
... , Feb. 4 Genoptix, Inc. (Nasdaq: GXDX ), ... report its financial results for the fourth quarter and full-year 2009 after ... 2010 . , A conference call hosted by President and CEO, ... will take place on the same day at 2:00pm PST ...
Cached Medicine Technology:Gorbec Pharmaceutical Services, Inc. Announces the Launch of Its GMP Analytical Laboratory in China 2Genoptix, Inc. to Announce Fourth Quarter and Full-Year 2009 Financial Results 2Genoptix, Inc. to Announce Fourth Quarter and Full-Year 2009 Financial Results 3
(Date:8/30/2014)... In today’s world, a good night’s sleep has ... sleep apnea (a medical problem where the airway collapses during ... of the rest they need to face their daily challenges. ... 20 million people in the United States alone have sleep ... and of those treated, many cannot tolerate their prescribed medical ...
(Date:8/30/2014)... August 30, 2014 Market Research ... 2009-2019 is a professional and in-depth market survey ... report firstly reviews the basic information of Lab ... The report then explores global and China’s top ... capacity, production value, and market share etc. , ...
(Date:8/30/2014)... 30, 2014 The federal judge ... ( http://www.injurybeacon.com/transvaginal-mesh/ ) filed against Boston Scientific Corp. ... cases selected for one of the proceeding’s bellwether ... 18, 2014, U.S. District Judge Joseph R. Goodwin ... with Boston Scientific’s contention that a consolidated trial ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has ... and sleep apnea (a medical problem where the airway ... their bed partners of the rest they need to ... population snores and 20 million people in the United ... have been diagnosed and treated; and of those treated, ...
(Date:8/30/2014)... August 30, 2014 Removecomplaints.net, a well-known ... industry, has announced to offer guarantee of results with ... offer this guarantee because of its tremendous track record. ... clients from all over the world and received recommendation ... job. , On being asked about the announcement, ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Removecomplaints.net Announces Guaranteed Complaints Removal Services 2
... Mann HealthDay Reporter , FRIDAY, Feb. 24 ... colonoscopies to screen for colon cancer during the recent ... high out-of-pocket costs often associated with this test, new ... to June 2009, about 500,000 fewer Americans who had ...
... 2012. John DeLuca, PhD, vice president for research at ... of the new Science Complex at William Paterson University,s College ... expert in cognitive function, will discuss "Neuroimaging, Brain and Behavior: ... to 1:05 pm in the Science East Lecture Hall. The ...
... almost 50 centers from across the U.S. and around ... sponsored by The Children,s Hospital of Philadelphia on Feb. ... 11 research abstracts selected by the conference organizers as ... physicians and 5 nurses. New Early Warning ...
... an automated external defibrillator if someone,s life depended on ... the United States, the answer, all too often when ... a Perspective piece published online this week in the ... from the Perelman School of Medicine at the University ...
... HealthDay Reporter , FRIDAY, Feb. 24 (HealthDay News) ... own take a companion -- usually a spouse or other ... researchers report. And they tend to bring the same ... system with another important member of a patient,s medical team, ...
... tumors., Invasion and metastasis were blocked by inhibition of ... clinical trials. PHILADELPHIA Dual inhibition of ... invasion and metastasis in a laboratory model of pancreatic ... Cancer Discovery , the newest journal of the American ...
Cached Medicine News:Health News:In Tougher Economy, Fewer Americans Get Colonoscopy 2Health News:In Tougher Economy, Fewer Americans Get Colonoscopy 3Health News:Kessler Foundation scientist addresses opening of science complex of William Paterson University 2Health News:Experts in pediatric heart disease present research at Cardiology 2012 conference 2Health News:Experts in pediatric heart disease present research at Cardiology 2012 conference 3Health News:Experts in pediatric heart disease present research at Cardiology 2012 conference 4Health News:Experts in pediatric heart disease present research at Cardiology 2012 conference 5Health News:Experts in pediatric heart disease present research at Cardiology 2012 conference 6Health News:Experts in pediatric heart disease present research at Cardiology 2012 conference 7Health News:Experts in pediatric heart disease present research at Cardiology 2012 conference 8Health News:Experts in pediatric heart disease present research at Cardiology 2012 conference 9Health News:A million chances to save a life 2Health News:A million chances to save a life 3Health News:Many Elderly Now Bring Companion on Doctor's Visit 2Health News:Many Elderly Now Bring Companion on Doctor's Visit 3Health News:Combined inhibition of VEGF and c-MET can decrease metastasis 2
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Elmed BC 50 M/M is an all purpose bipolar coagulator with a macro and micro mode. In the micro mode, the unit is ideally suitable for wet-field coagulation in ophthalmology, neurosurgery and other mi...
...
...
Medicine Products: